Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01736527 · ClinicalTrials.gov registry record · Phase 1
Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation
A Phase 1 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01736527 is a Phase 1 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 12 participants.
The verdict
NCT01736527, a Phase 1 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
To assess the levels of loteprednol etabonate (LE) in tear fluid following a single topical instillation of LE ophthalmic gel 0.5% formulation to healthy volunteers.
Interventions
- DRUG LE Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01736527
The ClinicalTrials.gov registry entry for NCT01736527 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LE Gel is the first listed.
NCT01736527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01736527 about?
NCT01736527 is a clinical study titled "Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation". To assess the levels of loteprednol etabonate (LE) in tear fluid following a single topical instillation of LE ophthalmic gel 0.5% formulation to healthy volunteers.
What is the current status of trial NCT01736527?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2013-01. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01736527?
The interventions under investigation include: LE Gel (DRUG).
Who is sponsoring clinical trial NCT01736527?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.